Cometriq
Active Ingredient(s): Cabozantinib S MalateFDA Approved: * November 29, 2012
Pharm Company: * EXELIXIS
Category: Cancer
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc. In November 2012, cabozantinib in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating ... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.2 Discussions
Dosage List
Related Brands
Drugs with the same active ingredientsPopular Topics
Lung cancer treated by cometriq ## Anyone out there living on cometriq? I am stage four lung cancer patient in remission...
2 REPLIESHello, I need to be able to get Cometriq for a cousin with Medullary Thyroid Cancer in Argentina. The only problem is th...
2 REPLIES